SCHEMBL2384317

SCHEMBL2384317

NNc1c(C(N)=O)c2c(N)ncnc2n1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 1.00
HSPA8 P11142 5/20 0.83
CDK2 P24941 3/20 0.74
CDK1 P06493 2/20 0.74
CCNA2 P20248 2/20 0.74
CCNA1 P78396 2/20 0.74
CCNB1 P14635 1/20 0.74
CDK5 Q00535 2/20 0.57
CDK5R1 Q15078 1/20 0.57
HSPA5 P11021 2/20 0.53
ADK P55263 4/20 0.52
DOT1L Q8TEK3 3/20 0.52
DCLK1 O15075 1/20 0.52
DAPK3 O43293 1/20 0.52
DYRK3 O43781 1/20 0.52
ROS1 P08922 1/20 0.52
RPS6KB1 P23443 1/20 0.52
FLT3 P36888 1/20 0.52
CSNK1A1 P48729 1/20 0.52
CSNK1D P48730 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12284814 1.00 HIF1A (1.00) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL29780006 1.00 HIF1A (1.00) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL2384313 1.00 HIF1A (1.00) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL20141370 0.90 HIF1A (0.81) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL22111064 0.90 HIF1A (0.81) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL20141362 0.88 HIF1A (0.79) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL22111053 0.87 HIF1A (0.77) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL30131081 0.87 HIF1A (0.77) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL20141988 0.87 HIF1A (0.77) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL20141359 0.86 HIF1A (0.75) HIF1AHSPA8CDK2CDK1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2214670-A2 COMPOUNDS FOR TREATING ABNORMAL CELLULAR PROLIFERATION Taiga Biotechnologies, Inc. (US) 2010-08-11 EP claimed
WO-2009059304-A2 COMPOUNDS FOR TREATING ABNORMAL CELLULAR PROLIFERATION TAIGA BIOTECHNOLOGIES, INC. (US) 2009-05-07 WO claimed
US-20240052418-A1 METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-02-15 US disclosed
US-11814681-B2 Method for predicting a subjects response to SLC modulator therapy THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-11-14 US disclosed
US-20210254158-A1 METHOD FOR PREDICTING A SUBJECTS RESPONSE TO SLC MODULATOR THERAPY RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. 2021-08-19 US disclosed
EP-3207048-A1 COMPOSITIONS AND METHODS OF TREATING MUSCULAR DYSTROPHY The Broad Institute, Inc. (US) 2017-08-23 EP disclosed
US-20170224758-A1 COMPOSITIONS AND METHODS OF TREATING MUSCULAR DYSTROPHY THE BROAD INSTITUTE, INC. (US) 2017-08-10 US disclosed
WO-2016061509-A1 COMPOSITIONS AND METHODS OF TREATNG MUSCULAR DYSTROPHY THE BROAD INSTITUTE, INC. (US) 2016-04-21 WO disclosed
US-8207136-B2 Nucleoside compounds and methods of use thereof THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2012-06-26 US disclosed
US-8207136-B2 Nucleoside compounds and methods of use thereof THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2012-06-26 US disclosed
US-8207136-B2 Nucleoside compounds and methods of use thereof THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2012-06-26 US disclosed
EP-2214670-A2 COMPOUNDS FOR TREATING ABNORMAL CELLULAR PROLIFERATION Taiga Biotechnologies, Inc. (US) 2010-08-11 EP disclosed
US-20090117651-A1 Nucleoside compounds and methods of use thereof THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2009-05-07 US disclosed
US-20090117651-A1 Nucleoside compounds and methods of use thereof THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2009-05-07 US disclosed
US-20090117651-A1 Nucleoside compounds and methods of use thereof THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2009-05-07 US disclosed
WO-2009059304-A2 COMPOUNDS FOR TREATING ABNORMAL CELLULAR PROLIFERATION TAIGA BIOTECHNOLOGIES, INC. (US) 2009-05-07 WO disclosed
EP-1876894-A1 NUCLEOSIDE COMPOUNDS AND METHODS OF USE THEREOF The Board of Trustees of the University of Illinois (US) 2008-01-16 EP disclosed
EP-1876894-A1 NUCLEOSIDE COMPOUNDS AND METHODS OF USE THEREOF The Board of Trustees of the University of Illinois (US) 2008-01-16 EP disclosed
WO-2006116512-A1 NUCLEOSIDE COMPOUNDS AND METHODS OF USE THEREOF THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, URBANA, IL (US) 2006-11-02 WO disclosed
WO-2006116512-A1 NUCLEOSIDE COMPOUNDS AND METHODS OF USE THEREOF THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, URBANA, IL (US) 2006-11-02 WO disclosed